← Back to patent-cliff list
Deoxythymidine/Deoxycytidine
Tier C — Watch / tradeDeoxythymidine/Deoxycytidine
Columbia University Medical Center
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Brand：Kygevvi
Indications (approved)：胸苷激酶2 (TK2) 缺乏症
Regional status
US
Approved
2025-11-03
EU
Approved
2026-03-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Deoxythymidine/Deoxycytidine?
Approved indications include: 胸苷激酶2 (TK2) 缺乏症.
When does the Deoxythymidine/Deoxycytidine patent expire?
No public expiry year is available for Deoxythymidine/Deoxycytidine yet; this page updates once verified.
How do I get a quote for Deoxythymidine/Deoxycytidine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01